US 2026/0265408 A1 · GD2-SPECIFIC CHIMERIC ANTIGEN RECEPTOR EFFECTOR CELLS FOR USE IN THE TREATMENT OF SOLID TUMORS, POSSIBLY IN COMBINATION WITH ENHANCER OF ZESTE HOMOLOG 2 (EZH2) INHIBITORS

Abstract

GD2-specific Chimeric Antigen Receptor effector cells for use in the treatment of solid tumors, possibly in combination with Enhancer of Zeste Homolog 2 (EZH2) inhibitors. —The present invention concerns a GD2 Specific Chimeric Antigen Receptor (GD2.CAR) effector cells for the treatment of solid tumours, in particular both extracranial GD2+ tumours (as soft and bone sarcomas, neuroblastoma, melanoma, lung cancer, bladder cancer and retinoblastoma) and brain tumours. Moreover, the present invention concerns also the use of GD2.CAR genetically modified effector cells in combination with Enhancer of Zeste Homolog 2 (EZH2) inhibitors for use in the treatment of solid tumors.

Claims28

Dependent claims

1-34. (canceled)

Anti-GD2 chimeric antigen receptor comprising, from the N-terminus to the C-terminus:

a) a signal peptide,
b) an anti GD2 single chain antibody domain,
c) a hinge,
d) a trans membrane domain,
e) at least two co-stimulatory signaling domains, and
f) CD3Zeta chain sequence,
wherein said anti GD2 single chain antibody domain comprises anti GD2 VL sequence and anti GD2 VH sequence linked each other by a linker, said linker being a short flexible glycines-rich linker with a length from 7 to 14 amino acids.

4 more elements

Dependencies are inferred from the claim text.

Facts

Application

19/489,204Filed 31 May 2024

Priority

IT 1020230000112501 Jun 2023

Published

10 Sep 2026

Term ends

Not estimatedThe source records don’t support an estimate.

Classification21 codes

C07K 16/3084
Against structure-related tumour-associated moieties: against tumour-associated gangliosides
A61K 40/11
Characterised by the cell type used: t-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer…
A61K 40/31
Characterised by the recombinant expression of specific molecules in the cells of the immune system: chimeric antigen receptors [CAR]
A61K 40/4258
Tumor associated carbohydrates: gangliosides, e.g. GM2, GD2 or GD3

Gd2-specific chimeric antigen receptor effector cells for use in the treatment of solid tumors, possibly in combination with enhancer of zeste homolog 2 (ezh2) inhibitors

Life of this patent

Gd2-specific chimeric antigen receptor effector cells for use in the treatment of solid tumors, possibly in combination with enhancer of zeste homolog 2 (ezh2) inhibitors

Life of this patent

Abstract

Claims28